Importantly, co-expression of GLI1 and two GLI1 targets, EGFR and Snail, are associated with worse outcome in breast cancer patients (Rudolph et al., 2018), further underscoring the clinical relevance of this pathway. The gene discussed is GLI1; the disease is breast cancer.